Your browser is no longer supported. Please, upgrade your browser.
Settings
BNTX [NASD]
BioNTech SE
Index- P/E76.69 EPS (ttm)5.40 Insider Own1.18% Shs Outstand243.12M Perf Week32.22%
Market Cap95.29B Forward P/E13.82 EPS next Y29.98 Insider Trans0.00% Shs Float214.95M Perf Month94.12%
Income1.42B PEG- EPS next Q9.01 Inst Own14.90% Short Float0.95% Perf Quarter142.69%
Sales2.98B P/S32.03 EPS this Y107.10% Inst Trans9.31% Short Ratio0.62 Perf Half Y251.16%
Book/sh12.32 P/B33.64 EPS next Y-14.80% ROA53.50% Target Price195.09 Perf Year398.30%
Cash/sh4.61 P/C89.88 EPS next 5Y- ROE88.30% 52W Range54.10 - 354.08 Perf YTD408.39%
Dividend- P/FCF- EPS past 5Y- ROI4.90% 52W High17.05% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin88.60% 52W Low666.06% ATR22.42
Employees2200 Current Ratio2.70 Sales Q/Q7294.90% Oper. Margin65.50% RSI (14)91.03 Volatility9.92% 7.50%
OptionableYes Debt/Eq0.23 EPS Q/Q- Profit Margin47.80% Rel Volume4.18 Prev Close351.81
ShortableYes LT Debt/Eq0.09 EarningsAug 09 BMO Payout0.00% Avg Volume3.27M Price414.44
Recom2.50 SMA2057.99% SMA5074.77% SMA200179.89% Volume13,636,281 Change17.80%
Jul-19-21Resumed Wolfe Research Outperform $248
Jun-16-21Downgrade Redburn Neutral → Sell $146
May-18-21Initiated Goldman Neutral $173
May-11-21Downgrade Bryan Garnier Buy → Neutral $135 → $206
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Aug-04-21 01:18PM  
12:28PM  
12:15PM  
11:19AM  
10:30AM  
09:23AM  
07:00AM  
03:08AM  
Aug-03-21 02:45PM  
02:25PM  
12:39PM  
12:26PM  
10:09AM  
05:52AM  
04:32AM  
Aug-02-21 04:50PM  
03:55PM  
01:55PM  
01:05PM  
01:01PM  
10:05AM  
08:42AM  
07:00AM  
03:20AM  
Aug-01-21 09:34AM  
07:51AM  
07:34AM  
06:33AM  
Jul-31-21 01:25PM  
08:02AM  
Jul-30-21 01:56PM  
01:34PM  
12:31PM  
06:02AM  
Jul-29-21 05:56PM  
02:27PM  
02:06PM  
10:32AM  
06:39AM  
06:00AM  
Jul-28-21 06:41PM  
03:45PM  
03:26PM  
02:21PM  
01:51PM  
09:56AM  
09:37AM  
08:19AM  
06:53AM  
06:48AM  
05:52AM  
02:52AM  
Jul-27-21 02:12PM  
10:00AM  
09:27AM  
05:52AM  
Jul-26-21 10:00PM  
09:44PM  
07:40PM  
05:45PM  
03:59PM  
03:48PM  
12:00PM  
11:53AM  
11:06AM  
10:00AM  
07:45AM  
Jul-25-21 06:31PM  
05:52AM  
Jul-23-21 01:53PM  
01:00PM  
10:58AM  
10:32AM  
10:09AM  
09:51AM  
09:50AM  
06:54AM  
06:45AM  
06:45AM  
06:02AM  
05:52AM  
Jul-22-21 08:00PM  
02:36PM  
11:00AM  
10:06AM  
Jul-21-21 08:00PM  
04:44PM  
03:17PM  
01:56PM  
01:43PM  
12:27PM  
10:45AM  
09:54AM  
07:47AM  
07:15AM  
07:15AM  
01:55AM  
Jul-20-21 11:46PM  
05:45PM  
02:51PM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.